Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
OFER LEVY · BOSTON CHILDREN'S HOSPITAL · 2020 · $2,426,447 — IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC): Clinical and Data Coordinating Center (CDCC) Project summary In December 2019, a cluster of respiratory illness in Wuhan, China defined the onset of a global pandemic involving a novel coronavirus (SARS-CoV-2) with associated respiratory di…
FRED R HIRSCH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $680,221 — ADMINISTRATIVE CORE: ABSTRACT Our inter-institutional U54 Serological Sciences Center of Excellence (“U54”) Administrative Core provides scientific and administrative oversight for all of the U54’s Projects and Cores. It also provides the main interface with patient advocates, NCI program staff, ex…
Mitchel A Rosen · RBHS-SCHOOL OF PUBLIC HEALTH · 2020 · $15,850 — Abstract The New Jersey / New York Hazardous Materials Worker Training Center will provide training for essential works to respond and work safely when faced with exposure to COVID-19. The Center will provide train-the-trainer course via distance web conferencing to expand the knowledge of trainers …
Daniel W Fitzgerald · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $632,901 — The COVID-19 pandemic has now spread from high- and middle-income countries to low-income countries, including Haiti and Tanzania. The natural history of COVID-19 is unknown in low-income countries. We propose to study a combined cohort of 3,054 adults in Haiti and Tanzania to determine the attack r…
Karla J F Satchell · NORTHWESTERN UNIVERSITY AT CHICAGO · 2020 · $1,578,942 — The goal of the Structural Genomics Centers for Infectious Diseases is to apply state-of-the-art, high-throughput structural biology technologies to experimentally characterize the three-dimensional atomic structure of targeted proteins on the NIAID Category A-C priority pathogens list and organisms…
THOMAS DENNY · DUKE UNIVERSITY · 2020 · $573,990 — The NIAID Division of AIDS has a requirement for the conduct of quantitative viral RNA measurements for assessment of HIV/SIV vaccine efficacy in preclinical studies with nonhuman primates. The NIAID provides immunological and virological support for nonhuman primate studies conducted at NIAID’s Sim…
TED ROSS · UNIVERSITY OF GEORGIA · 2020 · $969,655 — The Georgia University Research Foundation to support the National Cancer Institute's multi-site study seeking to determine if immune responses developed after confirmed infection with SARS-CoV-2.…
GREG WESTERGAARD · ALPHA GENESIS, INC. · 2020 · $4,607,948 — Quarantine and testing of imported animals; support for animal care and breeding programs; upgrades to facilities and equipment to enhance monitoring and housing of animals and to protect health of animals and staff by reducing potential for SARS-CoV2 transmission and spread within the colonies.…
JEFFREY GLENN · STANFORD UNIVERSITY · 2020 · $14,260,074 — To support the advanced development of a promising candidate therapeutic for NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development…
Jae U Jung · CLEVELAND CLINIC LERNER COM-CWRU · 2024 · $989,903 — Abstract Kaposi's sarcoma-associated herpesvirus (KSHV) is a prevalent virus that establishes a lifelong persistent infection in humans and is associated with Kaposi's sarcoma (KS) and primary effusion lymphomas (PELs). Despite the reduction in complications associated with HIV infection due to comb…
JAMES FRANCIS MARKMANN · UNIVERSITY OF PENNSYLVANIA · 2024 · $619,816 — PROJECT SUMMARY / ABSTRACT It has been suggested that the future of medicine rests in cell and gene therapy. While this assertion may be premature, it seems clear that these innovative therapies have extraordinary, paradigm shifting potential. For cell-based therapies, this is best exemplified by th…
Joel H Collier · DUKE UNIVERSITY · 2024 · $456,143 — Even when vaccines are rapidly developed and shown to be efficacious and safe, vaccination campaigns continue to be hampered by public hesitancy and by challenges distributing vaccines equitably around the globe. Vaccine hesitancy, where individuals refuse or delay vaccination, has been a persistent…
Michelle A Ozbun · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · 2024 · $190,625 — Project Summary Human papillomaviruses (HPVs) are highly transmissible causative agents of benign and malignant tumors/neoplasia in mucosal and cutaneous squamous epithelium. Papillomavirus (PV) disease is primarily driven by the viral early proteins, E6 and E7. Despite prophylactic vaccines that ca…
Parisa Yousefpour · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $40,682 — PROJECT SUMMARY Infectious diseases such as HIV, malaria, tuberculosis, and seasonal influenza epidemics and emergence of new pandemics remain major global health problems highlighting the need for innovative approaches in vaccine design. The precise kinetics of antigen exposure relative to inflamma…
Hannah Frizzell · ORLANCE, INC. · 2024 · $990,275 — PROJECT SUMMARY Orlance has developed a lead universal influenza (UFlu) DNA vaccine to address the need for a vaccine that can protect from annual influenza and the emergence of new variants that could cause future pandemics. Our UFlu vaccine is a multi-dose vaccine designed to induce systemic and m…
Xiaorong Lin · UNIVERSITY OF GEORGIA · 2024 · $577,663 — Abstract Cryptococcal meningoencephalitis (CME) is responsible for more than 15% of the total deaths of AIDS patients. The disease claims hundreds of thousands of lives each year, with global mortality rates of ~70% despite antifungal therapies. Unfortunately, there is no vaccine clinically availab…
Michelle Margaret Meyer · BOSTON COLLEGE · 2024 · $193,750 — Project Summary Streptococcus pneumoniae is a leading cause of pneumonia, acute otitis media (ear infection), and meningitis in the United States. S. pneumoniae remains an important pathogen despite a vaccine and effective antibiotic treatments due to increasing levels of antibiotic resistance and v…
Zhilong Yang · TEXAS A&M AGRILIFE RESEARCH · 2024 · $221,364 — Poxviruses are a large family of viruses including species that are highly pathogenic for humans and animals, including smallpox and monkeypox viruses. Some poxviruses are developed as vaccine vectors and oncolytic virotherapies to fight other infectious diseases and cancers. Vaccinia virus, the pro…
Joseph Edgar Craft · YALE UNIVERSITY · 2024 · $648,096 — PROJECT SUMMARY A novel vaccine for Lyme disease Acquired resistance to Ixodes scapularis, commonly known as “tick resistance”, can prevent transmission of Borrelia burgdorferi, the Lyme disease agent. We have shown that tick resistance can be generated in guinea pigs (1) repeatedly exposed to I. s…
Justin Richner · UNIVERSITY OF ILLINOIS AT CHICAGO · 2024 · $616,537 — Nearly 400 million people are infected with dengue virus (DENV) each year through the bite of infected mosquitos concentrated in the tropical and subtropical regions of the world. Symptoms can range from febrile illness to severe dengue that manifests as plasma leakage, sudden loss of blood pressure…